Is radioiodine more likely than antithyroid drugs to worsen ophthalmopathy in patients with Graves disease?

Rebecca S. Bahn

Research output: Contribution to journal › Article

1 Citation (Scopus)

Abstract

This Practice Point commentary discusses the findings and limitations of a systematic review by Acharya et al. that assessed the utility of radioiodine to treat Graves hyperthyroidism. The authors examined 10 randomized controlled trials, and focused on the potential causative relationship between radioiodine and Graves ophthalmopathy. They concluded that the risk of Graves ophthalmopathy following radioiodine therapy is higher than that after treatment with antithyroid drugs (relative risk [RR] 4.23). The risk of severe Graves ophthalmopathy was also found to be increased after treatment with radioiodine (RR 4.35). Glucocorticoid prophylaxis was highly effective in preventing disease progression in patients with pre-existing Graves ophthalmopathy (RR 0.03). Here, I highlight the issues to consider when interpreting and generalizing these results, such as the limitations imposed by the inconsistency of disease classification and description in the various trials. Although this systematic review highlighted the small but real risk of Graves ophthalmopathy progression following radioiodine therapy, it could not provide insight into the extent of this progression or identify which patients are at highest risk and so might benefit most from prophylaxis.

Original languageEnglish (US)
Pages (from-to)594-595
Number of pages2
JournalNature Clinical Practice Endocrinology and Metabolism
Volume4
Issue number11
DOIs
StatePublished - Nov 2008

Fingerprint

Antithyroid Agents
Graves Disease
Graves Ophthalmopathy
Hyperthyroidism
Therapeutics
Glucocorticoids
Disease Progression
Randomized Controlled Trials

Keywords

  • Antithyroid drugs
  • Graves disease
  • Graves ophthalmopathy
  • Hyperthyroidism
  • Radioiodine therapy

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Is radioiodine more likely than antithyroid drugs to worsen ophthalmopathy in patients with Graves disease? / Bahn, Rebecca S.

In: Nature Clinical Practice Endocrinology and Metabolism, Vol. 4, No. 11, 11.2008, p. 594-595.

Research output: Contribution to journal › Article

Bahn, RS 2008, 'Is radioiodine more likely than antithyroid drugs to worsen ophthalmopathy in patients with Graves disease?', Nature Clinical Practice Endocrinology and Metabolism, vol. 4, no. 11, pp. 594-595. https://doi.org/10.1038/ncpendmet0955
Bahn RS. Is radioiodine more likely than antithyroid drugs to worsen ophthalmopathy in patients with Graves disease? Nature Clinical Practice Endocrinology and Metabolism. 2008 Nov;4(11):594-595. https://doi.org/10.1038/ncpendmet0955
Bahn, Rebecca S. / Is radioiodine more likely than antithyroid drugs to worsen ophthalmopathy in patients with Graves disease?. In: Nature Clinical Practice Endocrinology and Metabolism. 2008 ; Vol. 4, No. 11. pp. 594-595.
@article{9611913006d54d5686d26815c65364af,
title = "Is radioiodine more likely than antithyroid drugs to worsen ophthalmopathy in patients with Graves disease?",
abstract = "This Practice Point commentary discusses the findings and limitations of a systematic review by Acharya et al. that assessed the utility of radioiodine to treat Graves hyperthyroidism. The authors examined 10 randomized controlled trials, and focused on the potential causative relationship between radioiodine and Graves ophthalmopathy. They concluded that the risk of Graves ophthalmopathy following radioiodine therapy is higher than that after treatment with antithyroid drugs (relative risk [RR] 4.23). The risk of severe Graves ophthalmopathy was also found to be increased after treatment with radioiodine (RR 4.35). Glucocorticoid prophylaxis was highly effective in preventing disease progression in patients with pre-existing Graves ophthalmopathy (RR 0.03). Here, I highlight the issues to consider when interpreting and generalizing these results, such as the limitations imposed by the inconsistency of disease classification and description in the various trials. Although this systematic review highlighted the small but real risk of Graves ophthalmopathy progression following radioiodine therapy, it could not provide insight into the extent of this progression or identify which patients are at highest risk and so might benefit most from prophylaxis.",
keywords = "Antithyroid drugs, Graves disease, Graves ophthalmopathy, Hyperthyroidism, Radioiodine therapy",
author = "Bahn, {Rebecca S.}",
year = "2008",
month = "11",
doi = "10.1038/ncpendmet0955",
language = "English (US)",
volume = "4",
pages = "594--595",
journal = "Nature Reviews Endocrinology",
issn = "1759-5029",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Is radioiodine more likely than antithyroid drugs to worsen ophthalmopathy in patients with Graves disease?

AU - Bahn, Rebecca S.

PY - 2008/11

Y1 - 2008/11

N2 - This Practice Point commentary discusses the findings and limitations of a systematic review by Acharya et al. that assessed the utility of radioiodine to treat Graves hyperthyroidism. The authors examined 10 randomized controlled trials, and focused on the potential causative relationship between radioiodine and Graves ophthalmopathy. They concluded that the risk of Graves ophthalmopathy following radioiodine therapy is higher than that after treatment with antithyroid drugs (relative risk [RR] 4.23). The risk of severe Graves ophthalmopathy was also found to be increased after treatment with radioiodine (RR 4.35). Glucocorticoid prophylaxis was highly effective in preventing disease progression in patients with pre-existing Graves ophthalmopathy (RR 0.03). Here, I highlight the issues to consider when interpreting and generalizing these results, such as the limitations imposed by the inconsistency of disease classification and description in the various trials. Although this systematic review highlighted the small but real risk of Graves ophthalmopathy progression following radioiodine therapy, it could not provide insight into the extent of this progression or identify which patients are at highest risk and so might benefit most from prophylaxis.

AB - This Practice Point commentary discusses the findings and limitations of a systematic review by Acharya et al. that assessed the utility of radioiodine to treat Graves hyperthyroidism. The authors examined 10 randomized controlled trials, and focused on the potential causative relationship between radioiodine and Graves ophthalmopathy. They concluded that the risk of Graves ophthalmopathy following radioiodine therapy is higher than that after treatment with antithyroid drugs (relative risk [RR] 4.23). The risk of severe Graves ophthalmopathy was also found to be increased after treatment with radioiodine (RR 4.35). Glucocorticoid prophylaxis was highly effective in preventing disease progression in patients with pre-existing Graves ophthalmopathy (RR 0.03). Here, I highlight the issues to consider when interpreting and generalizing these results, such as the limitations imposed by the inconsistency of disease classification and description in the various trials. Although this systematic review highlighted the small but real risk of Graves ophthalmopathy progression following radioiodine therapy, it could not provide insight into the extent of this progression or identify which patients are at highest risk and so might benefit most from prophylaxis.

KW - Antithyroid drugs

KW - Graves disease

KW - Graves ophthalmopathy

KW - Hyperthyroidism

KW - Radioiodine therapy

UR - http://www.scopus.com/inward/record.url?scp=54549104351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54549104351&partnerID=8YFLogxK

U2 - 10.1038/ncpendmet0955

DO - 10.1038/ncpendmet0955

M3 - Article

VL - 4

SP - 594

EP - 595

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

SN - 1759-5029

IS - 11

ER -

Access to Document